Found 7 matching trials
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas PHASE1 This is a phase 1/2, multicenter, dose-finding and dose expansion study of ...
Show More Location
Institut Jules Bordet
Learn More & Join Trial
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) PHASE2 This is a phase II, non-comparative, randomized study assessing combination...
Show More Status
Active Not Recruiting
Location
Institut Sainte Catherine
Learn More & Join Trial
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC PHASE2 TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study ...
Show More Status
Active Not Recruiting
Location
Clinique de l'Europe
Learn More & Join Trial
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure PHASE3 The aim of this clinical trial was to determine if the therapeutic cancer v...
Show More Location
East Valley Hematology and Oncology medical Group
Learn More & Join Trial
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor PHASE3 Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive ...
Show More Location
Clinical Research Advisors, LLC
Learn More & Join Trial
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study. PHASE2 This is a phase II randomized study investigating whether a combination mai...
Show More Location
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Learn More & Join Trial
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC PHASE2 The proposed study is an international randomized phase II, multicenter, op...
Show More Status
Active Not Recruiting
Learn More & Join Trial